Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany. The Idylla™ ctRAS liquid biopsy tests detect RAS mutations in patients with...
Read More »
Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform MRC Technology (‘MRCT’), a medical research charity, and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced a partnership to develop ...
Read More »
Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of its second liquid biopsy assay, the Idylla(TM) ...
Read More »
Exosome RNA Exosome RNA Research & Industry News
